Rituximab: Enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma

被引：10

作者：

Gisselbrecht, C ^{[1
]}

Mounier, N ^{[1
]}

机构：

[1] Hop St Louis, Inst Hematol, ERM 220, F-75475 Paris, France

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 01期

关键词：

D O I：

10.1053/sonc.2003.50022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：28 / 33

页数：6

共 31 条

[1]

Berinstein NL, 2002, BONE MARROW TRANSPL, V29, pS14, DOI 10.1038/sj.bmt.1703297

[2]

Bolwell BJ, 2001, BLOOD, V98, p738A

[3]

Bosly A, 2001, EUR J HAEMATOL, V66, P3

[4]

Brugger W, 2000, BLOOD, V96, p482A

[5]

Buckstein R, 2000, BLOOD, V96, p791A

[6]

Buckstein R, 1999, SEMIN ONCOL, V26, P115

[7]

Buckstein RJ, 2001, BLOOD, V98, p680A

[8]

EMMANOUILIDES C, 2001, BLOOD, V98, pB351

[9]

Flinn IW, 2001, BLOOD, V98, p676A

[10] European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma [J].

Foran, JM ;

Rohatiner, AZS ;

Cunningham, D ;

Popescu, RA ;

Solal-Celigny, P ;

Ghielmini, M ;

Coiffier, B ;

Johnson, PWM ;

Gisselbrecht, C ;

Reyes, F ;

Radford, JA ;

Bessell, EM ;

Souleau, B ;

Benzohra, A ;

Lister, TA .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) :317-324

← 1 2 3 4 →